HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場2019-2023

◆英語タイトル:Global HDAC (histone deacetylase) Inhibitors Market 2019-2023
◆商品コード:IRTNTR31116
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年3月29日
◆ページ数:117
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場について調査・分析し、市場概要、市場環境、HDAC(ヒストンデアセチラーゼ)阻害剤市場規模、投与経路別(経口HDAC阻害剤、非経口HDAC阻害剤)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場概要
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場環境
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場動向
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場規模
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:業界構造分析
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:投与経路別(経口HDAC阻害剤、非経口HDAC阻害剤)
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:地域別市場規模・分析
・HDAC(ヒストンデアセチラーゼ)阻害剤の北米市場規模・予測
・HDAC(ヒストンデアセチラーゼ)阻害剤のヨーロッパ・中東・アフリカ市場規模・予測
・HDAC(ヒストンデアセチラーゼ)阻害剤のアジア太平洋市場規模・予測
・HDAC(ヒストンデアセチラーゼ)阻害剤の主要国分析
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:意思決定フレームワーク
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:成長要因、課題
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:競争環境
・HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period. Chemotherapeutic drugs are increasingly being administered orally or intravenously for treating different tumors. However, there are instances that these active pharmaceutical ingredients often do not reach the targeted site in appropriate quantities, eventually, lowering the performance of the drugs. As a result, with the rising shift of research and prescription toward combination therapies using HDAC inhibitors, the market is expected to witness considerable growth during the forthcoming years. Technavio’s analysts have predicted that the HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.
Market Overview
High prevalence of oncology indications
One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications. The high growth in various types of cancers and neurologic conditions, coupled with high unmet need in the treatment landscape of these diseases will drive the growth of the market.
High costs associated with treatment
One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment. The high treatment costs act as a barrier for drug adoption, which reduces the patient base and poses a challenge to market growth.
For the detailed list of factors that will drive and challenge the growth of the HDAC (histone deacetylase) inhibitors market during 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated with the presence of a few market players. Companies are focusing on research on several other types of cancers using HDAC inhibitors due to their high target affinity and specificity. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Oral HDAC inhibitors – Market size and forecast 2018-2023
• Parenteral HDAC inhibitors – Market size and forecast 2018-2023
• Market opportunity by RoA
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• CELGENE CORPORATION
• Merck & Co., Inc.
• Novartis AG
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Spectrum Pharmaceuticals, Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Customer landscape
Exhibit 18: RoA – Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Oral HDAC inhibitors – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral HDAC inhibitors: Pipeline overview
Exhibit 22: Oral HDAC inhibitors – Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral HDAC inhibitors – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral HDAC inhibitors – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Prevalence of top 5 cancers newly reported in US 2015
Exhibit 43: Pipeline of combination therapies – Syndax
Exhibit 44: Treatment costs of HDAC inhibitors
Exhibit 45: Alternative treatment options for oncology conditions
Exhibit 46: Side effects of HDAC
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Some strategic alliances in global HDAC inhibitors market
Exhibit 49: drugs with respect to their cancer indications and expanded indications
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: CELGENE CORPORATION – Vendor overview
Exhibit 56: CELGENE CORPORATION – Business segments
Exhibit 57: CELGENE CORPORATION – Organizational developments
Exhibit 58: CELGENE CORPORATION – Geographic focus
Exhibit 59: CELGENE CORPORATION – Key offerings
Exhibit 60: CELGENE CORPORATION – Key customers
Exhibit 61: Merck & Co., Inc. – Vendor overview
Exhibit 62: Merck & Co., Inc. – Business segments
Exhibit 63: Merck & Co., Inc. – Organizational developments
Exhibit 64: Merck & Co., Inc. – Geographic focus
Exhibit 65: Merck & Co., Inc. – Segment focus
Exhibit 66: Merck & Co., Inc. – Key offerings
Exhibit 67: Merck & Co., Inc. – Key customers
Exhibit 68: Novartis AG – Vendor overview
Exhibit 69: Novartis AG – Business segments
Exhibit 70: Novartis AG – Organizational developments
Exhibit 71: Novartis AG – Geographic focus
Exhibit 72: Novartis AG – Segment focus
Exhibit 73: Novartis AG – Key offerings
Exhibit 74: Novartis AG – Key customers
Exhibit 75: Shenzhen Chipscreen Biosciences Co., Ltd. – Vendor overview
Exhibit 76: Shenzhen Chipscreen Biosciences Co., Ltd. – Organizational developments
Exhibit 77: Shenzhen Chipscreen Biosciences Co., Ltd. – Key offerings
Exhibit 78: Shenzhen Chipscreen Biosciences Co., Ltd. – Key customers
Exhibit 79: Spectrum Pharmaceuticals, Inc. – Vendor overview
Exhibit 80: Spectrum Pharmaceuticals, Inc. – Business segments
Exhibit 81: Spectrum Pharmaceuticals, Inc. – Organizational developments
Exhibit 82: Spectrum Pharmaceuticals, Inc. – Geographic focus
Exhibit 83: Spectrum Pharmaceuticals, Inc. – Key offerings
Exhibit 84: Spectrum Pharmaceuticals, Inc. – Key customers
Exhibit 85: Validation techniques employed for market sizing



【掲載企業】

CELGENE CORPORATION, Merck & Co., Inc., Novartis AG, Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[HDAC(ヒストンデアセチラーゼ)阻害剤の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆